Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Pardes Biosciences, Inc. PRDS NASDAQ

NASDAQ Global Market • Healthcare • Biotechnology • US • USD

SharesGrow Score
26/100
0/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Pardes Biosciences, Inc. (PRDS) is a Biotechnology company in the Healthcare sector, currently trading at $2.18. It has a SharesGrow Score of 25/100, indicating a weak investment profile with 0 out of 7 criteria passed.

Net income is $93M (loss), growing at -142.4%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $0 against $180M equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 9.81 (strong liquidity). Debt-to-assets is 0%. Total assets: $201M.

Analyst outlook: 1 / 3 analysts rate PRDS as buy (33%) — mixed sentiment.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 15/100 (Fail), Past 0/100 (Fail), Health 67/100 (Partial), Moat 28/100 (Fail), Future 20/100 (Fail), Income ?/100 (Fail).

PRDS SharesGrow Score Overview

33/100
SharesGrow Score
Below average — proceed with caution
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 67/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 28/100
Gross margin is + market cap
FUTURE 20/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — PRDS

—
VALUE N/A
N/A
No analyst coverage available for this stock.
✗
GROWTH Fail
15/100
PRDS: +0%/yr revenue is, -142.4%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
67/100
Balance sheet PRDS: Debt-to-Equity (D/E) ratio 0 (conservative), Current ratio is 9.81 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
28/100
PRDS: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 28/100. ≥ 70 = Pass.
View details →
✗
FUTURE Fail
20/100
Analyst outlook: 1 / 3 analysts rate PRDS as buy (33%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range0.75-3.67
Volume2.15M
Avg Volume (30D)509.69K
Market Cap$135.19M
Beta (1Y)0.42
Share Statistics
EPS (TTM)-1.61
Shares Outstanding$58.13M
IPO Date2021-12-27
Employees57
CEOThomas G. Wiggans
Financial Highlights & Ratios
EBITDA$-93.45M
Net Income$-93.45M
Operating Income$-99.82M
Total Cash$197.34M
Net Debt$-59.28M
Total Assets$200.62M
Price / Earnings (P/E)-1.4
Analyst Forecast
Rating ConsensusHold
Analysts Covering3
Buy 33% Hold 67% Sell 0%
Company Info
CountryUS
ExchangeNASDAQ Global Market
CurrencyUSD
ISINUS69945Q1058

Price Chart

Track all markets on TradingView
PRDS
Pardes Biosciences, Inc. ↗  ·  NASDAQ Global Market
Healthcare • Biotechnology
0.75 52WK RANGE 3.67

People Also View

NUVB
NUVB
Nuvation Bio Inc.
$4.85
+3.19%
 CTMX
CTMX
CytomX Therapeutics, Inc.
$4.54
+3.42%
 ASMB
ASMB
Assembly Biosciences, Inc.
$29.44
+0.68%
 OVID
OVID
Ovid Therapeutics Inc.
$2.96
+6.09%
 ELYM
ELYM
Eliem Therapeutics, Inc.
$5.11
-0.97%
 STTK
STTK
Shattuck Labs, Inc.
$6.78
+0.15%
 IPSC
IPSC
Century Therapeutics, Inc.
$2.37
+4.41%
 CNTB
CNTB
Connect Biopharma Holdings Limited
$3.05
+7.77%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message